Bridgewater Associates LP lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 53.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 18,723 shares of the life sciences company’s stock after selling 21,120 shares during the quarter. Bridgewater Associates LP’s holdings in Illumina were worth $3,249,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. First Citizens Bank & Trust Co. grew its stake in shares of Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after buying an additional 12 shares in the last quarter. Patten Group Inc. grew its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Puzo Michael J grew its stake in shares of Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after buying an additional 25 shares in the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of Illumina by 1.7% in the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after buying an additional 35 shares in the last quarter. Finally, Eqis Capital Management Inc. grew its stake in shares of Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after buying an additional 38 shares in the last quarter. Institutional investors and hedge funds own 93.34% of the company’s stock.

Illumina, Inc. (NASDAQ ILMN) traded down 0.45% on Friday, reaching $210.08. The company’s stock had a trading volume of 303,871 shares. The firm has a market capitalization of $30.67 billion, a PE ratio of 42.15 and a beta of 0.81. The stock’s 50 day moving average is $196.85 and its 200-day moving average is $180.11. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $214.04.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. The company had revenue of $662.00 million for the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.86 earnings per share. Analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Bridgewater Associates LP Sells 21,120 Shares of Illumina, Inc. (ILMN)” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/15/bridgewater-associates-lp-sells-21120-shares-of-illumina-inc-ilmn.html.

ILMN has been the subject of a number of recent research reports. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a research note on Wednesday, May 31st. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $195.00 target price for the company in a research note on Thursday, July 27th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and increased their target price for the company from $170.00 to $215.00 in a research note on Monday, August 7th. Argus increased their target price on Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company. Illumina has an average rating of “Hold” and an average price target of $181.76.

In other Illumina news, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the transaction, the director now owns 534,176 shares of the company’s stock, valued at approximately $91,221,235.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $178.21, for a total value of $3,564,200.00. Following the transaction, the director now directly owns 534,176 shares in the company, valued at approximately $95,195,504.96. The disclosure for this sale can be found here. Insiders sold a total of 195,434 shares of company stock worth $37,480,647 over the last three months. 1.60% of the stock is owned by company insiders.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.